S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

Keros Therapeutics Stock Forecast, Price & News

-0.93 (-1.97%)
(As of 01/21/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
131,457 shs
Average Volume
107,604 shs
Market Capitalization
$1.08 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive KROS News and Ratings via Email

Sign-up to receive the latest news and ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Keros Therapeutics logo

About Keros Therapeutics

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.


Julius Knowles
October 7, 2021 |  benzinga.com
Keros Therapeutics Insider Sold $510K In Company Stock
October 7, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$10 million
Book Value
$12.96 per share


Net Income
$-45.36 million
Pretax Margin




Free Float
Market Cap
$1.08 billion
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.17 out of 5 stars

Medical Sector

436th out of 1,418 stocks

Pharmaceutical Preparations Industry

200th out of 684 stocks

Analyst Opinion: 3.5Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -

Keros Therapeutics (NASDAQ:KROS) Frequently Asked Questions

Is Keros Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Keros Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Keros Therapeutics stock.
View analyst ratings for Keros Therapeutics
or view top-rated stocks.

When is Keros Therapeutics' next earnings date?

Keros Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for Keros Therapeutics

How were Keros Therapeutics' earnings last quarter?

Keros Therapeutics, Inc. (NASDAQ:KROS) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.87) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.72) by $0.15.
View Keros Therapeutics' earnings history

What price target have analysts set for KROS?

4 equities research analysts have issued twelve-month price targets for Keros Therapeutics' stock. Their forecasts range from $70.00 to $100.00. On average, they expect Keros Therapeutics' stock price to reach $86.67 in the next twelve months. This suggests a possible upside of 87.2% from the stock's current price.
View analysts' price targets for Keros Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Keros Therapeutics' key executives?

Keros Therapeutics' management team includes the following people:
  • Dr. Jasbir Seehra, Pres, CEO, Treasurer, & Director (Age 65, Pay $787.16k)
  • Mr. Keith C. Regnante, Chief Financial Officer (Age 51, Pay $518.57k)
  • Dr. Jennifer Lachey Ph.D., Chief Scientific Officer (Age 49, Pay $524.92k)
  • Ms. Esther Cho J.D., Head of Legal & Corp. Sec.
  • Dr. Claudia Ordonez M.D., Chief Medical Officer (Age 55)

What other stocks do shareholders of Keros Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Keros Therapeutics investors own include AbbVie (ABBV), Brainstorm Cell Therapeutics (BCLI), Cloudera (CLDR), CVS Health (CVS), Inovio Pharmaceuticals (INO), Iovance Biotherapeutics (IOVA), Karyopharm Therapeutics (KPTI), Neurocrine Biosciences (NBIX), Novavax (NVAX) and Pfizer (PFE).

When did Keros Therapeutics IPO?

(KROS) raised $75 million in an initial public offering (IPO) on Wednesday, April 8th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, SVB Leerink and Piper Sandler served as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

What is Keros Therapeutics' stock symbol?

Keros Therapeutics trades on the NASDAQ under the ticker symbol "KROS."

How do I buy shares of Keros Therapeutics?

Shares of KROS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Keros Therapeutics' stock price today?

One share of KROS stock can currently be purchased for approximately $46.30.

How much money does Keros Therapeutics make?

Keros Therapeutics has a market capitalization of $1.08 billion and generates $10 million in revenue each year. The company earns $-45.36 million in net income (profit) each year or ($2.71) on an earnings per share basis.

How many employees does Keros Therapeutics have?

Keros Therapeutics employs 35 workers across the globe.

What is Keros Therapeutics' official website?

The official website for Keros Therapeutics is www.kerostx.com.

Where are Keros Therapeutics' headquarters?

How can I contact Keros Therapeutics?

Keros Therapeutics' mailing address is 99 HAYDEN AVENUE SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER, LEXINGTON MA, 02421. The company can be reached via phone at 617-314-6297 or via email at [email protected].

This page was last updated on 1/22/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.